FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095410198> ?p ?o ?g. }

• W2095410198 endingPage "472" @default.
• W2095410198 startingPage "467" @default.
• W2095410198 abstract "The inhibition of canalicular glycoprotein transporters has been suggested as the cause of familial intrahepatic cholestasis. Mutations in multidrug resistance 3-glycoprotein (MDR3) gene induce progressive familial intrahepatic cholestasis type 3 (PFIC3). Phenotypically, mutation in mdr2 in mice resembles the disruption of MDR3 in human. Secondly, mutation in the bile salt exporting pump (BSEP)/sister of P-glycoprotein (spgp) gene causes progressive familial intrahepatic cholestasis type 2 in human. However, in spgp knock-out mice only a mild persistent cholestasis occurs. The aim of this study is to evaluate the effects of various P-glycoprotein (Pgp) transporters on bile formation and the canalicular transport of taurocholic acid (TCA) in an attempt to understand the combined role of these transporters in the pathogenesis of familial intrahepatic cholestasis. Total bile acid (TBA) and cholic acid secretion rate were decreased in the mdr2 knock-out mice. However, bile flow (BF) and the secretion of muricholic acids were increased. Secretion of cholesterol was negligible and no phospholipids were detected in bile of mdr2 knock-out mice. Treatment with cyclosporine A (CsA) decreased the BF, and the biliary secretion of bile salts (BS) and phospholipids as compared to wild type mice, but after the injection of TCA+CsA, the BF, and the biliary secretion of BS and lipids were increased as compared to the wild type mice treated with CsA alone. In the mdr2 knock-out mice, CsA treatment decreased the BF and the secretion of BS but after the injection of TCA+CsA, the BF and the biliary secretion of BS were increased and the phospholipid secretion was slightly stimulated as compared to the mdr2 knock-out mice treated with CsA alone.Disruption of the mdr2 gene and the inhibition of glycoprotein transporters by CsA induce cholestasis in mice which is characterized by reduced BF, BS and biliary lipid secretion. However, CsA treatment did not significantly increase the cholestatic effect in the mdr2 knock-out mice. The injection of TCA decreased the cholestatic effect in the mdr2 knock-out mice as well as the inhibition of glycoproteins transporters by CsA. These data suggest that mutation in the canalicular mdr2 is an important factor during the development of progressive familial cholestasis." @default.
• W2095410198 created "2016-06-24" @default.
• W2095410198 creator A5033830713 @default.
• W2095410198 date "2003-11-01" @default.
• W2095410198 modified "2023-09-30" @default.
• W2095410198 title "Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice" @default.
• W2095410198 cites W134482844 @default.
• W2095410198 cites W1508412813 @default.
• W2095410198 cites W1513897103 @default.
• W2095410198 cites W1751757376 @default.
• W2095410198 cites W1825809852 @default.
• W2095410198 cites W1958141434 @default.
• W2095410198 cites W1981451793 @default.
• W2095410198 cites W2007234960 @default.
• W2095410198 cites W2021018323 @default.
• W2095410198 cites W2026850269 @default.
• W2095410198 cites W2037675065 @default.
• W2095410198 cites W2050007442 @default.
• W2095410198 cites W2059292726 @default.
• W2095410198 cites W2061569374 @default.
• W2095410198 cites W2073035603 @default.
• W2095410198 cites W2093277109 @default.
• W2095410198 cites W2098628139 @default.
• W2095410198 cites W2101494642 @default.
• W2095410198 cites W2122566192 @default.
• W2095410198 cites W2143808974 @default.
• W2095410198 cites W2145891424 @default.
• W2095410198 cites W2168474068 @default.
• W2095410198 cites W2168526937 @default.
• W2095410198 cites W2172134989 @default.
• W2095410198 cites W2188361714 @default.
• W2095410198 cites W2316681446 @default.
• W2095410198 cites W2325002157 @default.
• W2095410198 doi "https://doi.org/10.1016/s1043-6618(03)00187-7" @default.
• W2095410198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12967592" @default.
• W2095410198 hasPublicationYear "2003" @default.
• W2095410198 type Work @default.
• W2095410198 sameAs 2095410198 @default.
• W2095410198 citedByCount "9" @default.
• W2095410198 countsByYear W20954101982014 @default.
• W2095410198 countsByYear W20954101982023 @default.
• W2095410198 crossrefType "journal-article" @default.
• W2095410198 hasAuthorship W2095410198A5033830713 @default.
• W2095410198 hasConcept C104317684 @default.
• W2095410198 hasConcept C126322002 @default.
• W2095410198 hasConcept C133936738 @default.
• W2095410198 hasConcept C134018914 @default.
• W2095410198 hasConcept C149011108 @default.
• W2095410198 hasConcept C185592680 @default.
• W2095410198 hasConcept C2775900799 @default.
• W2095410198 hasConcept C2778132995 @default.
• W2095410198 hasConcept C2778593092 @default.
• W2095410198 hasConcept C2778707650 @default.
• W2095410198 hasConcept C2779399885 @default.
• W2095410198 hasConcept C2779609443 @default.
• W2095410198 hasConcept C2780480987 @default.
• W2095410198 hasConcept C2910800957 @default.
• W2095410198 hasConcept C2911091166 @default.
• W2095410198 hasConcept C36201501 @default.
• W2095410198 hasConcept C44312359 @default.
• W2095410198 hasConcept C49039625 @default.
• W2095410198 hasConcept C501593827 @default.
• W2095410198 hasConcept C55493867 @default.
• W2095410198 hasConcept C71924100 @default.
• W2095410198 hasConcept C86803240 @default.
• W2095410198 hasConceptScore W2095410198C104317684 @default.
• W2095410198 hasConceptScore W2095410198C126322002 @default.
• W2095410198 hasConceptScore W2095410198C133936738 @default.
• W2095410198 hasConceptScore W2095410198C134018914 @default.
• W2095410198 hasConceptScore W2095410198C149011108 @default.
• W2095410198 hasConceptScore W2095410198C185592680 @default.
• W2095410198 hasConceptScore W2095410198C2775900799 @default.
• W2095410198 hasConceptScore W2095410198C2778132995 @default.
• W2095410198 hasConceptScore W2095410198C2778593092 @default.
• W2095410198 hasConceptScore W2095410198C2778707650 @default.
• W2095410198 hasConceptScore W2095410198C2779399885 @default.
• W2095410198 hasConceptScore W2095410198C2779609443 @default.
• W2095410198 hasConceptScore W2095410198C2780480987 @default.
• W2095410198 hasConceptScore W2095410198C2910800957 @default.
• W2095410198 hasConceptScore W2095410198C2911091166 @default.
• W2095410198 hasConceptScore W2095410198C36201501 @default.
• W2095410198 hasConceptScore W2095410198C44312359 @default.
• W2095410198 hasConceptScore W2095410198C49039625 @default.
• W2095410198 hasConceptScore W2095410198C501593827 @default.
• W2095410198 hasConceptScore W2095410198C55493867 @default.
• W2095410198 hasConceptScore W2095410198C71924100 @default.
• W2095410198 hasConceptScore W2095410198C86803240 @default.
• W2095410198 hasIssue "5" @default.
• W2095410198 hasLocation W20954101981 @default.
• W2095410198 hasLocation W20954101982 @default.
• W2095410198 hasOpenAccess W2095410198 @default.
• W2095410198 hasPrimaryLocation W20954101981 @default.
• W2095410198 hasRelatedWork W1606649779 @default.
• W2095410198 hasRelatedWork W2003517015 @default.
• W2095410198 hasRelatedWork W2004283172 @default.
• W2095410198 hasRelatedWork W2037536556 @default.
• W2095410198 hasRelatedWork W2078033160 @default.
• W2095410198 hasRelatedWork W2095410198 @default.

• next